SuperworthProtagonist Therapeutics market cap PTGX
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Oct 23, 2026
- $9B
- Highest close in our data
- $10B
- Aug 2026
Protagonist Therapeutics is worth $9B at the close on Oct 23, 2026, at $138.43 a share.
That is up 92% over the last year and up 505% over five years.
Its highest close in our data was $10B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $9B | $5B | $10B | +61% |
| 2025 | $5.6B | $2.2B | $6B | +139% |
| 2024 | $2.3B | $1.3B | $2.8B | +76% |
| 2023 | $1.3B | $573.7M | $1.7B | +146% |
| 2022 | $536.8M | $356.6M | $1.7B | −67% |
| 2021 | $1.6B | $790M | $2.3B | +112% |
| 2020 | $771.3M | $154.2M | $912.4M | +305% |
| 2019 | $190.4M | $167.9M | $408.9M | +24% |
| 2018 | $153.8M | $127.2M | $487.1M | −64% |
| 2017 | $426M | $138.6M | $426M | +16% |
| 2016 | $367.6M | $235.9M | $426.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| PTGXProtagonist Therapeutics | $9B |
| CORTCorcept Therapeutics | $9.3B |
| TGTXTG Therapeutics | $8.3B |
| BMRNBiomarin Pharmaceutical | $10.8B |
| ALKSAlkermes plc. | $7.3B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| JAZZJazz Pharmaceuticals | $13.9B |
| INDVIndivior Pharmaceuticals | $4.1B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $6.9B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Protagonist Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.